Welcome to our dedicated page for Walgreen Boots news (Ticker: WBA), a resource for investors and traders seeking the latest updates and insights on Walgreen Boots stock.
This page provides a focused view of news and announcements historically associated with Walgreens Boots Alliance, Inc. (formerly Nasdaq: WBA) and its related businesses, including Walgreens and Walgreens Specialty Pharmacy. Company communications highlight Walgreens as a U.S. retail pharmacy brand founded in 1901 that serves nearly 9 million customers and patients each day across approximately 8,500 stores in the U.S. and Puerto Rico, and Walgreens Boots Alliance as a pharmacy-led health and wellbeing enterprise formed through the combination of Walgreens and Alliance Boots.
News related to WBA and Walgreens has covered several key themes. One major area is corporate transactions and capital markets activity. In 2025, a series of announcements detailed the Agreement and Plan of Merger under which Blazing Star Merger Sub, Inc. merged with and into Walgreens Boots Alliance, Inc., resulting in the company becoming a wholly owned subsidiary of Blazing Star Parent, LLC, an affiliate of Sycamore Partners. Related releases described tender offers and consent solicitations for various series of Walgreens Boots Alliance and Walgreen Co. notes, pricing terms, extensions of expiration times and settlement dates, and the final results of these offers.
Another important news category involves the company’s transition from public to private ownership. A Form 8-K filed on August 28, 2025 describes the completion of the merger, the cash consideration and divested asset proceed rights received by shareholders, and the cessation of trading of WBA common stock and certain notes on Nasdaq. A subsequent Form 25 documents the removal of these securities from listing, and a Form 15 filed on September 8, 2025 terminates registration and suspends reporting obligations. Sycamore Partners separately announced the completion of its acquisition of Walgreens Boots Alliance, Inc. and its intention that Walgreens, The Boots Group, Shields Health Solutions, CareCentrix and VillageMD operate as standalone companies under private ownership.
Operational and healthcare-focused news also features prominently. Walgreens Specialty Pharmacy announced an expansion of its limited distribution drug network to 265 products, emphasizing its role in specialty medications for patients with rare, complex and chronic diseases and its independence from pharmacy benefit managers. Walgreens has also issued releases on vaccination services, including nationwide flu shot availability for individuals three years and older, walk-in and scheduled appointments, digital check-in features and incentives for myWalgreens members receiving vaccines.
Investors and observers using this news page can review historical coverage of WBA’s merger process, debt tender offers, governance and shareholder actions, as well as Walgreens’ specialty pharmacy initiatives and vaccination programs. For those tracking the evolution of the company, these articles collectively document WBA’s path from a publicly traded integrated healthcare and retail group to a privately held organization under Sycamore Partners, while also illustrating how Walgreens positions its pharmacies and specialty operations within the broader healthcare landscape.
Walgreens (WBA) has announced the availability of flu shots nationwide for individuals aged 3 and up. The company offers flexible vaccination appointments, including nights, weekends, and walk-ins, with options to schedule additional vaccines in the same visit. Walgreens will also provide the updated COVID-19 vaccine once available.
The pharmacy chain offers various testing options for flu and COVID-19, including a rapid test for both viruses with results in 30 minutes. Walgreens pharmacists in many states can evaluate and prescribe antiviral medications for flu or COVID-19. The company also provides 1-hour delivery for medicine cabinet essentials and Same Day Rx Delivery for eligible prescriptions.
According to a 2023 IQVIA study, approximately 70% of adult flu vaccinations were administered in retail pharmacies during flu season. Since 2010, Walgreens pharmacy team members have administered more than 105 million vaccinations in U.S. communities.
Walgreens has received a $25 million award from BARDA to conduct a Phase IV observational clinical study on COVID-19 vaccine data. The study aims to assess Correlates of Protection (CoP) and enhance U.S. public health preparedness. Walgreens will leverage its community pharmacy network to improve access and diversity in clinical trials.
Key points:
- Study will enroll up to 4,000 participants across 20 retail pharmacy locations
- Walgreens has administered over 90 million COVID-19 vaccinations to date
- The project is part of HHS's $5 billion Project NextGen initiative
- Walgreens will use its decentralized clinical trial platform for participant recruitment
Walgreens is launching Nice! For You, a new tier of its popular owned grocery brand, Nice!, to help customers make healthier food and beverage choices. The new line features over 150 products without artificial flavors, sweeteners, synthetic dyes, or high-fructose corn syrup. Many options are also organic and gluten-free.
Nice! For You aims to support customers' journeys to healthier lifestyles while maintaining Walgreens' commitment to high-quality, great-tasting products at competitive prices. The portfolio includes a wide range of items such as jerky, oatmeal, nuts, trail mixes, dried fruit, coffee, frozen foods, beverages, and various grocery staples.
Walgreens Boots Alliance (WBA) has appointed Dr. William H. Shrank to its board of directors. Dr. Shrank brings significant healthcare strategy and policy expertise, having held leadership roles at Humana, CVS Health, and Andreesen Horowitz. His appointment comes at a pivotal time as WBA focuses on strategic turnaround and enhancing its community pharmacy value. CEO Tim Wentworth and Executive Chairman Stefano Pessina expressed confidence that Dr. Shrank's experience will be instrumental in driving long-term value for stakeholders.
Walgreens Boots Alliance (WBA) has declared a quarterly dividend of 25 cents per share, consistent with the previous quarter. The dividend will be payable on September 12, 2024, to shareholders recorded by August 21, 2024. Walgreens Boots Alliance and its predecessor, Walgreen Co., have sustained a remarkable streak of paying dividends over 367 consecutive quarters, equivalent to 91 years.
Walgreens announced its sponsorship for the second consecutive year at the Friends for Life (FFL) conference hosted by Children with Diabetes (CWD). The event, taking place from July 9-14 in Orlando, Fla, aims to provide education and support to families living with type 1 diabetes. Walgreens will showcase a range of diabetes management products, including blood glucose meters, A1C test kits, and first-aid essentials, and highlight its use of Instacart's Scan & Pay technology for convenient purchasing. Key speakers include Tracey D. Brown, Walgreens EVP and chief customer officer, and Shauna Markes-Wilson, director of pharmacy and retail operations. The event will also focus on clinical trials and recruiting healthcare professionals.
Walgreens Boots Alliance (WBA) reported its fiscal 2024 third-quarter results, revealing a complex financial landscape. The company posted a Q3 earnings per share (EPS) of $0.40, up from $0.14 in the previous year, but adjusted EPS decreased by 36.6% to $0.63 due to lower sale-leaseback gains and a challenging U.S. retail environment. Sales grew 2.6% year-over-year to $36.4 billion. However, fiscal 2024 adjusted EPS guidance has been lowered to $2.80-$2.95, reflecting ongoing challenges in the pharmacy sector and U.S. consumer market.
WBA is finalizing a multiyear footprint optimization program to close underperforming U.S. stores and plans to enhance the U.S. Retail Pharmacy experience. Despite a 2.3% increase in U.S. Retail Pharmacy sales to $28.5 billion, adjusted operating income declined by 47.9%, impacted by reimbursement pressures. The International segment saw a 2.8% sales increase to $5.7 billion, while U.S. Healthcare sales rose by 7.6% to $2.1 billion.
Year-to-date results show a 6.2% sales increase to $110.1 billion, but WBA faced a net loss of $5.6 billion, up from a $2.9 billion loss in the previous year, mainly due to significant impairment charges.
Walgreens announces a special Independence Day discount offer for veterans, active-duty military personnel, and their families. From July 4 to July 7, valid military ID holders can enjoy a 20% discount on eligible regular-price products at Walgreens and Duane Reade stores nationwide. Additionally, all customers can get a 15% discount on online orders of $35 or more from June 30 to July 6 using code STARS15. The myWalgreens loyalty program offers further savings opportunities, including up to $30 in Walgreens Cash rewards each month. Walgreens ensures convenience with in-store shopping, 1-hour and 24-hour delivery options, and 30-minute pickup services. Regular Walgreens stores will operate on standard hours during Independence Day, while some pharmacies may have hours.
On June 27, Walgreens is collaborating with KFF's Greater Than HIV initiative to offer free rapid HIV and STD testing at over 550 Walgreens stores, making it the largest National HIV Testing Day event in the nation.
The initiative also includes free rapid syphilis and/or hepatitis C testing at many locations. This partnership aims to provide accessible testing and connect individuals to local prevention and treatment services.
HIV rapid test manufacturers, including Abbott Laboratories and OraSure Technologies, are donating tests. Since 2011, the partnership has provided over 82,000 free HIV tests. This year marks the program’s highest participation level.
Walgreens Boots Alliance (Nasdaq: WBA) will announce its fiscal 2024 third-quarter results on June 27, 2024. The results will be released at 7 a.m. ET, followed by a conference call with WBA management at 8:30 a.m. ET.
The call will be simulcast on the WBA investor relations website and a replay will be available for 12 months.